Trial reportChest2012
Macrolide antibiotics and survival in patients with acute lung injury.
Trial report in Chest, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it.
- JAID/JSC Guidelines for the Treatment of Respiratory Infectious Diseases: The Japanese Association for Infectious Diseases/Japanese Society of Chemotherapy - The JAID/JSC Guide to Clinical Management of Infectious Disease/Guideline-preparing Committee Respiratory Infectious Disease WG.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2016Guideline
- Efficacy of combination therapy with oseltamivir phosphate and azithromycin for influenza: a multicenter, open-label, randomized study.PloS one · 2014Trial
- The preventive effect and mechanism of Tibetan medicine Aconitum tanguticum (Maxim.) Stapf on acute lung injury.Chinese medicine · 2025Article
- Acute exacerbation of idiopathic pulmonary fibrosis a narrative review primary focus on treatments.Journal of thoracic disease · 2024Review
- Application of anti-inflammatory treatment in two different ovine Acute Respiratory Distress Syndrome injury models: a preclinical randomized intervention study.Scientific reports · 2023Article
- Article
- Potential treatments of COVID-19: Drug repurposing and therapeutic interventions.Journal of pharmacological sciences · 2023Review
- Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine.Medicina (Kaunas, Lithuania) · 2023Article
- Therapeutic effects and mechanism of Atractylodis rhizoma in acute lung injury: Investigation based on an Integrated approach.Frontiers in pharmacology · 2023Article
- Effect of erythromycin on mortality and the host response in critically ill patients with sepsis: a target trial emulation.Critical care (London, England) · 2022Article
- Additional effect of azithromycin over β-lactam alone for severe community-acquired pneumonia-associated acute respiratory distress syndrome: a retrospective cohort study.Pneumonia (Nathan Qld.) · 2022Article
- Acute exacerbation of interstitial lung disease in the intensive care unit.World journal of critical care medicine · 2022Review
- Antibiotics as immunomodulators: a potential pharmacologic approach for ARDS treatment.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Immunomodulation of endothelial cells induced by macrolide therapy in a model of septic stimulation.Immunity, inflammation and disease · 2021Article
- Azithromycin in viral infections.Reviews in medical virology · 2021Review
- Could Azithromycin Be Part ofFrontiers in microbiology · 2021Review
- Rationale for azithromycin in COVID-19: an overview of existing evidence.BMJ open respiratory research · 2021Review
- Preventing the development of severe COVID-19 by modifying immunothrombosis.Life sciences · 2021Review
- GSK3 modulation in acute lung injury, myocarditis and polycystic kidney disease-related aneurysm.Biochimica et biophysica acta. Molecular cell research · 2020Review
- Erythromycin inhibits neutrophilic inflammation and mucosal disease by upregulating DEL-1.JCI insight · 2020Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
2 authors.
Funding
Abstract
backgroundAnimal models suggest that immunomodulatory properties of macrolide antibiotics have therapeutic value for patients with acute lung injury (ALI). We investigated the association between receipt of macrolide antibiotics and clinical outcomes in patients with ALI.
methodsSecondary analysis of multicenter, randomized controlled trial data from the Acute Respiratory Distress Syndrome Network Lisofylline and Respiratory Management of Acute Lung Injury Trial, which collected detailed data regarding antibiotic use among participants with ALI.
resultsForty-seven of 235 participants (20%) received a macrolide antibiotic within 24 h of trial enrollment. Among patients who received a macrolide, erythromycin was the most common (57%), followed by azithromycin (40%). The median duration of macrolide use after study enrollment was 4 days (interquartile range, 2-8 days). Eleven of the 47 (23%) patients who received macrolides died, compared with 67 of the 188 (36%) who did not receive a macrolide (P = .11). Participants administered macrolides were more likely to have pneumonia as an ALI risk factor, were less likely to have nonpulmonary sepsis or to be randomized to low tidal volume ventilation, and had a shorter length of stay prior to trial enrollment. After adjusting for potentially confounding covariates, use of macrolide was associated with lower 180-day mortality (hazard ratio [HR], 0.46; 95% CI, 0.23-0.92; P = .028) and shorter time to successful discontinuation of mechanical ventilation (HR, 1.93; 95% CI, 1.18-3.17; P = .009). In contrast, fluoroquinolone (n = 90) and cephalosporin antibiotics (n = 93) were not associated with improved outcomes.
conclusionsReceipt of macrolide antibiotics was associated with improved outcomes in patients with ALI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.